Glanzmann's thrombasthenia risk factors

Glanzmann's thrombasthenia
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glanzmann's thrombasthenia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Glanzmann's thrombasthenia risk factors On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Glanzmann's thrombasthenia risk factors All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Glanzmann's thrombasthenia risk factors
CDC on Glanzmann's thrombasthenia risk factors
Glanzmann's thrombasthenia risk factors in the news
Blogs on Glanzmann's thrombasthenia risk factors
Directions to Hospitals Treating Type page name here
Risk calculators and risk factors for Glanzmann's thrombasthenia risk factors

• Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The risk of Glanzmann's thrombathenia in children coming from consanguineous marriage is much higher.

Autoantibodies are another important cause of acquired GT .

Risk Factors

The autoantibodies production can be result of following conditions:

• Hematologic disorders and malignancies, such as :

1. acute lymphoblastic leukemia,
2. non-Hodgkin’s lymphoma
3. multiple myeloma
4. hairy cell leukemia
5. myelodysplastic syndrome
6. immune thrombocytopenic purpura (ITP)

• Autoimmune diseases, such as lupus (Blickstein et al)
• Drugs : anti-thrombotic drugs use , like abciximab, eptifibatide, and tirofiban which all antagonize αIIbβ3
• platelet transfusions.[6]